Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wondrack L et al. | Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8849266 |
| Nalca Y et al. | Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. | 2006 | Antimicrob. Agents Chemother. | pmid:16641435 |
| Dunne MW et al. | Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. | 2003 | Antimicrob. Agents Chemother. | pmid:12878537 |
| Batt SL et al. | Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. | 2003 | Antimicrob. Agents Chemother. | pmid:12936971 |
| Henry DC et al. | Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12936972 |
| Derouin F et al. | Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1324642 |
| Vallée E et al. | Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. | 1992 | Antimicrob. Agents Chemother. | pmid:1324644 |
| Merchan LM et al. | Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. | 2015 | Antimicrob. Agents Chemother. | pmid:25385115 |
| Mertens JC et al. | Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. | 1992 | Antimicrob. Agents Chemother. | pmid:1324645 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Pajukanta R et al. | In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. | 1992 | Antimicrob. Agents Chemother. | pmid:1329617 |
| Bonnet M and Van der Auwera P | In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. | 1992 | Antimicrob. Agents Chemother. | pmid:1329619 |
| Phimda K et al. | Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. | 2007 | Antimicrob. Agents Chemother. | pmid:17638700 |
| Koetsveld J et al. | Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents. | 2017 | Antimicrob. Agents Chemother. | pmid:28674060 |
| Michot JM et al. | Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. | 2004 | Antimicrob. Agents Chemother. | pmid:15215125 |
| Ng LK et al. | Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. | 2002 | Antimicrob. Agents Chemother. | pmid:12183262 |
| Hoberman A and Paradise JL | Study design questions in treatment of children with acute otitis media. | 2004 | Antimicrob. Agents Chemother. | pmid:15215151 |
| Matsui H et al. | Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. | 2005 | Antimicrob. Agents Chemother. | pmid:16048953 |
| Prunier AL et al. | Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. | 2002 | Antimicrob. Agents Chemother. | pmid:12183270 |
| Collins SA et al. | Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. | 2017 | Antimicrob. Agents Chemother. | pmid:27919896 |
| Ngo LY et al. | Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. | 1999 | Antimicrob. Agents Chemother. | pmid:10348786 |
| Walsh M et al. | In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:3038010 |
| Koirala KD et al. | Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. | 2012 | Antimicrob. Agents Chemother. | pmid:22371897 |
| Binet R et al. | Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. | 2010 | Antimicrob. Agents Chemother. | pmid:20065052 |
| Ohara T et al. | Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. | 2002 | Antimicrob. Agents Chemother. | pmid:12384353 |
| Cigana C et al. | Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. | 2007 | Antimicrob. Agents Chemother. | pmid:17210769 |
| Farrell DJ et al. | Results from the Solithromycin International Surveillance Program (2014). | 2016 | Antimicrob. Agents Chemother. | pmid:27044551 |
| Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
| Ouyang-Latimer J et al. | In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. | 2011 | Antimicrob. Agents Chemother. | pmid:21115800 |
| Fischer JH et al. | Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. | 2012 | Antimicrob. Agents Chemother. | pmid:22106226 |
| Jepras RI et al. | Rapid assessment of antibiotic effects on Escherichia coli by bis-(1,3-dibutylbarbituric acid) trimethine oxonol and flow cytometry. | 1997 | Antimicrob. Agents Chemother. | pmid:9303401 |
| Heifets L et al. | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8031351 |
| Vazifeh D et al. | Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9333032 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Sugimura M et al. | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. | 2008 | Antimicrob. Agents Chemother. | pmid:18676884 |
| Shima K et al. | Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia. | 2013 | Antimicrob. Agents Chemother. | pmid:23478971 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Roblin PM and Hammerschlag MR | Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. | 1998 | Antimicrob. Agents Chemother. | pmid:9449287 |
| Goodman CD et al. | Chemobiosynthesis of new antimalarial macrolides. | 2013 | Antimicrob. Agents Chemother. | pmid:23208707 |
| Kim MK et al. | Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. | 2002 | Antimicrob. Agents Chemother. | pmid:12234843 |
| Amsden GW et al. | Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. | 1999 | Antimicrob. Agents Chemother. | pmid:9869584 |
| Critchley IA et al. | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. | 2007 | Antimicrob. Agents Chemother. | pmid:17908940 |
| Pérez-MartÃnez I and Haas D | Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. | 2011 | Antimicrob. Agents Chemother. | pmid:21537014 |
| Goswick SM and Brenner GM | Activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis. | 2003 | Antimicrob. Agents Chemother. | pmid:12543653 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Breitschwerdt EB et al. | Efficacy of doxycycline, azithromycin, or trovafloxacin for treatment of experimental Rocky Mountain spotted fever in dogs. | 1999 | Antimicrob. Agents Chemother. | pmid:10103185 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. | 2001 | Antimicrob. Agents Chemother. | pmid:11302832 |
| Welsh L et al. | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8787907 |
| Schroeck JL et al. | Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. | 2015 | Antimicrob. Agents Chemother. | pmid:25870064 |
| Nagaoka K et al. | Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23380724 |